Redeye takes a neutral view on Fortnox as the stock is trading slightly above our Base Case despite a strong Q4 resulting in a raised Base Case. The strong net customer intake and transaction-based revenue growth drove the sales beat and OPEX was lower than anticipated.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking.www.redeye.se/

Attachments

Fortnox - Stronger Numbers Despite Macro Headwinds

© Modular Finance, source Nordic Press Releases